The Prevalence of Hepatitis C Infection in Blood Donors: A Meta-Analysis and Systematic Review
PDF
HTML

Keywords

Hepatitis C
Prevalence
Meta-Analysis
Blood Donors
Blood Safety

How to Cite

Kasraian, L., Hosseini, S., Salehi Marzijarani , M., Ebrahimi, A., & Ashkani-Esfahani, S. (2020). The Prevalence of Hepatitis C Infection in Blood Donors: A Meta-Analysis and Systematic Review. Iranian Red Crescent Medical Journal, 22(1). Retrieved from https://ircmj.com/index.php/IRCMJ/article/view/474

Abstract

Context: Hepatitis C virus (HCV) infection is one of the major bloodborne diseases worldwide. Although many screening tests were introduced and utilized for blood donations, as the main source of HCV transmission, it has still remained a global concern.

Evidence Acquisition: The prevalence of HCV infection among blood donors in every country and every WHO region was investigated. A Comprehensive electronic systematic search algorithm in the international databases PubMed, ISI, Scopus, and ProQuest were adopted for articles published until October 2016, using the following keywords: ("Blood Donors" OR "blood donation" OR "donor" OR "donation" OR "blood" OR "blood safety" OR "bloodborne" OR "residual risk" OR "transfusion-transmitted infections") AND ("prevalence" OR "epidemiology") in combination with “hepatitis C” OR “HCV” for hepatitis C. Only cross-sectional studies, which had appropriate measurement and sampling methods, were selected.

Results: The review of the literature showed that the global prevalence of HCV was 854.09 in 100,000. The highest and lowest rates of HCV among WHO divisions were seen in the African region by 2503.61 and the European region by 450.21 in 100,000, respectively. The highest and lowest rates among the countries were seen in Cambodia by 14,670 and Netherlands by 25.370 in 100,000.

Conclusions: It seems that strategies for prevention of HCV infection in blood donations should be considered for the policymakers; low prevalence countries are suggested to share their knowledge and countries with lower socioeconomic status should be aided to control the HCV infection among their blood donors.

PDF
HTML

References

  1. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74 ( Pt 11):2391-9. doi: 10.1099/0022-1317-74-11-2391. [PubMed: 8245854].
  2. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Lankarani KB. Hepatitis B virus infection in Iran: A systematic review. Hepat Mon.
  3. Global Burden of Hepatitis C. Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44(1):20-9. doi: 10.1177/0091270003258669. [PubMed: 14681338].
  4. Smith DB, Mellor J, Jarvis LM, Davidson F, Kolberg J, Urdea M, et al. Variation of the hepatitis C virus 5' non-coding region: Implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group. J Gen Virol. 1995;76 ( Pt 7):1749-61. doi: 10.1099/0022-1317-76-7-1749. [PubMed: 9049380].
  5. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107-15. doi: 10.1111/j.1469-0691.2010.03432.x. [PubMed: 21091831].
  6. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81. doi: 10.1111/j.1478-3231.2008.01934.x. [PubMed: 19207969].
  7. Chou R, Clark EC, Helfand M; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;140(6):465-79. doi: 10.7326/0003-4819-140-6-200403160-00014. [PubMed: 15023713].
  8. Alter MJ, Kuhnert WL, Finelli L; Centers for Disease Control Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52(RR-3):1-13. quiz CE1-4. [PubMed: 12585742].
  9. Centers for Disease Control and Prevention. Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR Recomm Rep. 2013;62(18):362-5.
  10. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335-74. doi: 10.1002/hep.22759. [PubMed: 19330875].
  11. Alter MJ, Margolis HS. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47(RR-19):1-39. [PubMed: 9790221].
  12. Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327(6):369-73. doi: 10.1056/NEJM199208063270601. [PubMed: 1320736].
  13. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):41-6. doi: 10.7150/ijms.3.41. [PubMed: 16614741]. [PubMed Central: PMC1415844].
  14. Nyaga VN, Arbyn M, Aerts M. Metaprop: A Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):39. doi: 10.1186/2049-3258-72-39. [PubMed: 25810908]. [PubMed Central: PMC4373114].
  15. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25(6):646-54. doi: 10.1177/0272989X05282643. [PubMed: 16282215].
  16. World Health Organization. Definition of regional groupings. 2017.
  17. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-42. doi: 10.1002/hep.26141. [PubMed: 23172780].
  18. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004;351(8):760-8. doi: 10.1056/NEJMoa040085. [PubMed: 15317889].
  19. Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int. 2013;33 Suppl 1:68-79. doi: 10.1111/liv.12063. [PubMed: 23286849]. [PubMed Central: PMC4110680].
  20. Mohaghegh Shalmani H, Ranjbar M, Mohammad Alizadeh AH. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Journal of Liver. 2014;3(2). doi: 10.4172/2167-0889.1000147.
  21. Carey W. Tests and screening strategies for the diagnosis of hepatitis C. Cleve Clin J Med. 2003;70 Suppl 4:S7-13. doi: 10.3949/ccjm.70.suppl_4.s7. [PubMed: 14558640].
  22. Henderson DK, Dembry L, Fishman NO, Grady C, Lundstrom T, Palmore TN, et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol. 2010;31(3):203-32. doi: 10.1086/650298. [PubMed: 20088696].